Literature DB >> 12935442

Measurement of nitric oxide in murine Hepatoma Hepa1c1c7 cells by reversed phase HPLC with fluorescence detection.

Negar Gharavi1, Ayman O S El-Kadi.   

Abstract

PURPOSE: Nitric oxide (NO) is produced by various cell types in picomolar to nanomolar range and has important roles in a variety of biological functions. The aim of the present study was to investigate a sensitive and reproducible fluorometric HPLC method for measuring nitrite, one of the stable oxidation products of nitric oxide, in murine hepatoma Hepa 1c1c7 cells.
METHODS: Hepa 1c1c7 cells were incubated with vehicle or recombinant murine tumor necrosis factor-alpha (TNF-alpha, 10 ng/ml) in Hanks' balanced salt solution (HBSS) for 10 hours. Thereafter, the HBSS medium was collected for nitrite analysis. NO production was examined by measuring the conversion of 2, 3-diaminonaphthalene (DAN) to its fluorescent product, 2, 3-naphthotriazole (NAT). NAT was analyzed after elution with 60% of 15 mM sodium phosphate buffer (pH = 7.5) and 40% methanol through a 10-microm reversed-phase C18 column (250 x 4.00 mm, I.D.) at a flow rate of 1 ml /min. Fluorescence was monitored with excitation at 375 nm and emission at 415 nm.
RESULTS: NAT appeared in approximately 16 min with no interference peaks. The assay yielded linear response within the examined range of 10 - 200 pM (r(2) >0.99) with an intra and inter-day variability of <10 % and accuracy of > 90%. The detection limit for nitrite was 10 pM. NO production by TNF- alpha treated Hepa 1c1c7 cells is estimated to be approximately 2 folds more than untreated cells.
CONCLUSION: This fluorometric HPLC assay offers a sensitive and reliable measurement of NO production in cell culture medium.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12935442

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  7 in total

1.  Increased nitric oxide (NO) pathway metabolites in the vitreous fluid of patients with rhegmatogenous retinal detachment or diabetic traction retinal detachment.

Authors:  Roselie M H Diederen; Ellen C La Heij; Nicolaas E P Deutz; Alfons G H Kessels; Hans M H van Eijk; Fred Hendrikse
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-11-03       Impact factor: 3.117

2.  Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats.

Authors:  G Wölkart; X Pang; H Stessel; M Kirchengast; F Brunner
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

3.  Tadalafil Integrates Nitric Oxide-Hydrogen Sulfide Signaling to Inhibit High Glucose-induced Matrix Protein Synthesis in Podocytes.

Authors:  Hak Joo Lee; Denis Feliers; Meenalakshmi M Mariappan; Kavithalakshmi Sataranatarajan; Goutam Ghosh Choudhury; Yves Gorin; Balakuntalam S Kasinath
Journal:  J Biol Chem       Date:  2015-03-09       Impact factor: 5.157

4.  Inhibition of macrophage activation by the myxoma virus M141 protein (vCD200).

Authors:  Leiliang Zhang; Marianne Stanford; Jia Liu; Catherine Barrett; Lei Jiang; A Neil Barclay; Grant McFadden
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

5.  Stable isotope-assisted LC-MS/MS monitoring of glyceryl trinitrate bioactivation in a cell culture model of nitrate tolerance.

Authors:  Elizabeth R Axton; Elizabeth A Hardardt; Jan F Stevens
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-12-24       Impact factor: 3.205

6.  Quantification of nitric oxide by high-performance liquid chromatography-fluorometric method in subgenomic hepatitis C virus-replicon expressing Huh7 cells upon treatment with acetylsalicylic acid.

Authors:  Clara Patricia Rios-Ibarra; Victor Torres-De La Cruz; Andrea Gabriela Ochoa-Ruiz; Ana María Rivas-Estilla
Journal:  Exp Ther Med       Date:  2018-07-24       Impact factor: 2.447

7.  Evaluation of the immunity activity of glycyrrhizin in AR mice.

Authors:  Xiao-Lan Li; Ai-Guo Zhou
Journal:  Molecules       Date:  2012-01-12       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.